NCT02163421View on ClinicalTrials.gov

Bioavailability and Pharmacokinetics of Vedolizumab in Healthy Participants Following Single Subcutaneous Administration

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

December 31, 2014

Study Completion Date

January 31, 2015

Conditions
Healthy
Interventions
DRUG

Vedolizumab SC

Vedolizumab injection, for subcutaneous use (vedolizumab SC)

DRUG

Vedolizumab IV

Vedolizumab injection, for intravenous use (vedolizumab IV)

Trial Locations (2)

NW10 7EW

London

Unknown

London

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY

NCT02163421 - Bioavailability and Pharmacokinetics of Vedolizumab in Healthy Participants Following Single Subcutaneous Administration | Biotech Hunter | Biotech Hunter